Recent clinical trials have demonstrated that PD-1/PD-L1 blockades can lead to durable responses in diverse malignancies, including melanoma, NSCLC, and renal cell carcinoma (66). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.